Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.03.007
Abstract: In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus… read more here.
Keywords: plus prednisone; abiraterone; abiraterone acetate; acetate plus ... See more keywords
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study
Sign Up to like & getrecommendations! Published in 2020 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyaa030
Abstract: Abstract Background LATITUDE was a randomized, double-blind, international and phase 3 study of abiraterone acetate plus prednisone in patients with high-risk metastatic hormone-naïve prostate cancer. In the first interim analysis of LATITUDE (clinical cutoff date:… read more here.
Keywords: plus prednisone; analysis; abiraterone acetate; acetate plus ... See more keywords